Pruritus News and Research

RSS
Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

Good news for patients suffering from shingles

Good news for patients suffering from shingles

Cipher acquires worldwide rights to three products from Astion

Cipher acquires worldwide rights to three products from Astion

FDA approves Fluzone Intradermal Quadrivalent vaccine to prevent four strains of influenza virus

FDA approves Fluzone Intradermal Quadrivalent vaccine to prevent four strains of influenza virus

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Vanda reports total revenues of $14.8 million for third quarter 2014

Vanda reports total revenues of $14.8 million for third quarter 2014

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Incyte’s ruxolitinib Phase III study for polycythemia vera achieves primary endpoint

Incyte’s ruxolitinib Phase III study for polycythemia vera achieves primary endpoint

Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC